Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. Founded in 1993, the firm provides integrated solutions across the entire drug discovery and early development pipeline. Evotec’s service offering spans target identification, assay development, high-throughput screening, medicinal chemistry, in vitro and in vivo pharmacology, ADME/Tox, and manufacturing support. By combining proprietary technologies with specialized expertise, the company supports pharmaceutical, biotechnology and academic partners in advancing novel therapeutic candidates.
The company operates through a collaborative business model, entering partnerships and alliances with major global pharma companies as well as emerging biotech ventures. Evotec’s Innovative Medicines Partnerships (IMP) segment focuses on risk-and-reward collaborations in areas such as neurology, oncology, metabolic disease and infectious diseases. In addition, Evotec maintains a proprietary pipeline of small molecules and biologics, leveraging its technological platforms to progress internal drug candidates toward clinical proof of concept.
Evotec maintains research and development facilities across Europe, North America and Asia, including hubs in Germany, the United Kingdom, France and the United States. This geographic footprint enables the company to access diverse talent pools and cater to cross-border client needs. Advanced laboratory infrastructure, automated screening platforms and specialized chemistry units allow Evotec to deliver tailored research programs at scale, from early target validation through to lead optimization and preclinical development.
Under the leadership of CEO Christian Kullmann since 2018, Evotec has expanded its service capabilities through strategic acquisitions and technology investments. The executive team, supported by an experienced supervisory board, emphasizes scientific innovation, operational excellence and sustainable growth. By fostering a collaborative culture and forging long-term partnerships, Evotec aims to accelerate drug discovery and bring new therapies to patients around the world.
AI Generated. May Contain Errors.
